Study of liver functions and some biomarkers in leukemia patients

Background: Acute lymphocytic leukemia (ALL) is a severe form of leukemia marked by an excess of lymphoblasts or lymphocytes in the bone marrow and peripheral circulation. While hepatitis is a well-known consequence of acute lymphoblastic leukemia treatment, the link between aberrant liver biochemistry and early leukemia presentation is poorly understood. The aim of this study is to assess the state of liver function in those with acute leukemia by monitoring the activities of alkaline phosphatase (ALP), aspartate aminotransferase (AST) , and alanine aminotransferase (ALT) , levels of bilirubin, as well as assessing the impact of ALL on other variables including calcium and phosphorus. Methods: In this research, 40 ALL patients and a control group of 40 healthy individuals were included in the study. The functioning of the liver was examined by measuring the activities of ALT, AST, ALP, and bilirubin levels in blood samples. Besides that, measuring serum calcium and phosphorus levels. Results: In accordance with the findings, there were substantial differences in ALT, AST, ALP, and bilirubin between the control and patient groups. In addition, there were a significant differences between patients and controls regarding the serum content of calcium and phosphorus. Conclusions: A liver function test should be done on leukemia patients before treatment, according to this study, which found that blood ALT, AST, ALP, and bilirubin levels are high at the time of acute leukemia diagnosis.